RLMD - Relmada Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Relmada Therapeutics, Inc.

880 Third Avenue
12th Floor
New York, NY 10022
United States
646-876-3459
http://www.relmada.com

SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees4

Key Executives

NameTitlePayExercisedYear Born
Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBACEO & Director392.5kN/A1960
Dr. Ottavio V. Vitolo M.D.Sr. VP, Head of R&D and Chief Medical Officer330kN/A1972
Mr. Charles S. EnceChief Financial OfficerN/AN/A1965
Ms. Gina DiGuglielmoVP & Head of Clinical OperationsN/AN/AN/A
Dr. Richard M. ManganoConsultantN/AN/A1950
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, and proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.

Corporate Governance

Relmada Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.